JetBlue To Begin New York-Guayaquil Flight This December

JetBlue Airways Corporation (NASDAQ:JBLU) will launch an additional flight to Guayaquil, Ecuador, beginning Dec 5, 2019. Once operational, this nonstop daily flight from New York’s John F. Kennedy International Airport will be the longest route in JetBlue’s network. Tickets on the route are currently available for sale.

The new service will expand JetBlue’s base in Ecuador as well as in South America. This February, the carrier commenced operations in Guayaquil from Fort Lauderdale. (Read more: JetBlue Boosts South American Base With Flights to Guayaquil). Additionally, the airline operates daily between Fort Lauderdale and Quito. Notably, Guayaquil marks the sixth city served by JetBlue in South America.

The airline’s move to penetrate the prosperous Ecuador market is noteworthy as it tries to attract traffic on the New York-Guayaquil route, which “suffers from high fares and limited service choices”.

The carrier will operate on the route via the fuel-efficient Airbus A321neo aircraft featuring premium facilities, such as luxurious seating and infight entertainment services for an enhanced customer experience.

JetBlue Airways Corporation Price

JetBlue Airways Corporation price | JetBlue Airways Corporation Quote

Zacks Rank & Key Picks

JetBlue carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader Transportation sector are SkyWest, Inc. (NASDAQ:SKYW) , GATX Corporation (NYSE:GATX) and Fly Leasing Limited (NYSE:FLY) . While Fly Leasing sports a Zacks Rank #1 (Strong Buy), SkyWest and GATX carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Shares of SkyWest and Fly Leasing have surged more than 35% and 55%, respectively, so far this year. Meanwhile, GATX flaunts a stellar earnings history, having surpassed the Zacks Consensus Estimate in each of the preceding four quarters, the average being 16%.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>